Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?

Valdés P, Schneider BL.

Front Neuroanat. 2016 Dec 20;10:123. doi: 10.3389/fnana.2016.00123. eCollection 2016. Review.

2.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Epub 2016 Sep 5. Review.

PMID:
27519465
3.

Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes.

Nagae LM, Honce JM, Tanabe J, Shelton E, Sillau SH, Berman BD.

Front Neuroanat. 2016 Feb 23;10:17. doi: 10.3389/fnana.2016.00017. eCollection 2016.

4.

Initiation of calorie restriction in middle-aged male rats attenuates aging-related motoric decline and bradykinesia without increased striatal dopamine.

Salvatore MF, Terrebonne J, Fields V, Nodurft D, Runfalo C, Latimer B, Ingram DK.

Neurobiol Aging. 2016 Jan;37:192-207. doi: 10.1016/j.neurobiolaging.2015.10.006. Epub 2015 Oct 19.

5.

Parkinson disease and incidental Lewy body disease: Just a question of time?

Iacono D, Geraci-Erck M, Rabin ML, Adler CH, Serrano G, Beach TG, Kurlan R.

Neurology. 2015 Nov 10;85(19):1670-9. doi: 10.1212/WNL.0000000000002102. Epub 2015 Oct 14.

6.

Three-dimensional and stereological characterization of the human substantia nigra during aging.

Di Lorenzo Alho AT, Suemoto CK, Polichiso L, Tampellini E, de Oliveira KC, Molina M, Santos GA, Nascimento C, Leite RE, de Lucena Ferreti-Rebustini RE, da Silva AV, Nitrini R, Pasqualucci CA, Jacob-Filho W, Heinsen H, Grinberg LT.

Brain Struct Funct. 2016 Sep;221(7):3393-403. doi: 10.1007/s00429-015-1108-6. Epub 2015 Sep 19.

7.

Reduced Number of Pigmented Neurons in the Substantia Nigra of Dystonia Patients? Findings from Extensive Neuropathologic, Immunohistochemistry, and Quantitative Analyses.

Iacono D, Geraci-Erck M, Peng H, Rabin ML, Kurlan R.

Tremor Other Hyperkinet Mov (N Y). 2015 May 13;5. pii: tre-5-301. doi: 10.7916/D8T72G9G. eCollection 2015.

8.

Regenerative Medicine for the Aging Brain.

Lopez-Leon M, Reggiani PC, Herenu CB, Goya RG.

Enliven J Stem Cell Res Regen Med. 2014;1(1):1-9.

9.

Parkinson's disease as a result of aging.

Rodriguez M, Rodriguez-Sabate C, Morales I, Sanchez A, Sabate M.

Aging Cell. 2015 Jun;14(3):293-308. doi: 10.1111/acel.12312. Epub 2015 Feb 9. Review.

10.

Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Rice MW, Roberts RC, Melendez-Ferro M, Perez-Costas E.

Brain Struct Funct. 2016 Jan;221(1):185-201. doi: 10.1007/s00429-014-0901-y. Epub 2014 Oct 1.

11.

Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice.

Wu KC, Lu YH, Peng YH, Tsai TF, Kao YH, Yang HT, Lin CJ.

J Cereb Blood Flow Metab. 2015 Jan;35(1):37-47. doi: 10.1038/jcbfm.2014.162. Epub 2014 Sep 24.

12.

The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging.

Rodriguez M, Morales I, Rodriguez-Sabate C, Sanchez A, Castro R, Brito JM, Sabate M.

Front Neuroanat. 2014 Aug 7;8:80. doi: 10.3389/fnana.2014.00080. eCollection 2014. Review.

13.

Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat.

Healy-Stoffel M, Omar Ahmad S, Stanford JA, Levant B.

Brain Res. 2014 Jul 29;1574:113-9. doi: 10.1016/j.brainres.2014.05.045. Epub 2014 Jun 9.

14.

A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease.

Perea RD, Rada RC, Wilson J, Vidoni1 ED, Morris JK, Lyons KE, Pahwa R, Burns JM, Honea RA.

J Alzheimers Dis Parkinsonism. 2013 Aug 26;3:123.

15.

Ageing and Parkinson's disease: why is advancing age the biggest risk factor?

Reeve A, Simcox E, Turnbull D.

Ageing Res Rev. 2014 Mar;14:19-30. doi: 10.1016/j.arr.2014.01.004. Epub 2014 Feb 3. Review.

16.
17.

Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Martin LJ, Semenkow S, Hanaford A, Wong M.

Neurobiol Aging. 2014 May;35(5):1132-52. doi: 10.1016/j.neurobiolaging.2013.11.008. Epub 2013 Nov 16.

18.

Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem.

Bardou I, Kaercher RM, Brothers HM, Hopp SC, Royer S, Wenk GL.

Neurobiol Aging. 2014 May;35(5):1065-73. doi: 10.1016/j.neurobiolaging.2013.11.006. Epub 2013 Nov 19.

19.

Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM.

Nat Neurosci. 2013 Oct;16(10):1392-400. doi: 10.1038/nn.3500. Epub 2013 Aug 25. Erratum in: Nat Neurosci. 2015 Dec;18(12):1861.

20.

Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats.

Healy-Stoffel M, Ahmad SO, Stanford JA, Levant B.

Neurosci Lett. 2013 Jun 24;546:26-30. doi: 10.1016/j.neulet.2013.04.033. Epub 2013 May 2.

Supplemental Content

Support Center